News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
BioSpace News Archive
Browse BioSpace’s published news and press releases by year, month, and day.
12 Results
Year
2005 (24679)
2006 (34770)
2007 (39687)
2008 (39410)
2009 (42118)
2010 (39616)
2011 (38383)
2012 (38416)
2013 (36268)
2014 (39673)
2015 (44433)
2016 (38330)
2017 (37191)
2018 (39124)
2019 (51338)
2020 (57666)
2021 (58724)
2022 (53928)
2023 (42568)
2024 (38486)
2025 (17535)
Month
January (4345)
February (4356)
March (4476)
April (4722)
May (4999)
June (4103)
July (3643)
August (3330)
September (4039)
October (5056)
November (4470)
December (3799)
Day
1 (21)
2 (28)
3 (291)
4 (299)
5 (210)
6 (198)
7 (88)
8 (20)
9 (26)
10 (204)
11 (264)
12 (223)
13 (206)
14 (127)
15 (5)
16 (12)
17 (183)
18 (268)
19 (197)
20 (202)
21 (95)
22 (5)
23 (6)
24 (193)
25 (218)
26 (195)
27 (217)
28 (97)
29 (2)
30 (3)
Year
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Month
January
February
March
April
May
June
July
August
September
October
November
December
Day
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
Deals
MiMedx Continues to Fight against Holding 2019 Annual Meeting
MiMedx Shareholder Group issued the following statement to fellow shareholders of MiMedx Group, Inc.:
June 16, 2019
·
3 min read
Drug Development
Amgen Announces BLINCYTO® (blinatumomab) Five-Year Overall Survival Data At EHA 2019
Phase 2 Single-Arm BLAST Study Shows Median Overall Survival of 36.5 Months in Patients With Minimal Residual Disease-Positive Acute Lymphoblastic Leukemia
June 16, 2019
·
24 min read
Previous
2 of 2